Heparin in Placental Dysfunction

Fetal Safety Profile

The American College of Cardiology states that low-molecular-weight heparin (LMWH) does not cross the placenta and poses no direct fetal risk, due to its large molecular size, preventing fetal exposure 1, 2
No teratogenic potential exists with heparin compounds, unlike warfarin which causes embryopathy in 4-10% of exposures 2
No risk of fetal bleeding complications occurs with LMWH 1

The American College of Cardiology recommends monitoring anti-Xa levels 4-6 hours after morning dose, targeting 0.7-1.2 units/mL 2
Adjusting dosing as pregnancy progresses is necessary due to changes in volume of distribution with weight gain, as suggested by the Journal of the American College of Cardiology 3
Continuing LMWH throughout pregnancy until several weeks before delivery is advised by the Journal of the American College of Cardiology 3

The bleeding risk during antepartum period is 1.41% (95% CI 0.62-2.41%) and 1.20% (95% CI 0.3-2.50%) in the first 24 hours after delivery, according to Blood advances 4
LMWH should not be used in patients with glomerular filtration rate <30 mL/min; UFH with aPTT monitoring is preferred in significant renal dysfunction, as stated by Blood advances 4
Heparin-induced thrombocytopenia risk appears low during pregnancy but requires platelet monitoring, as reported by Blood advances 4

In heparin-induced thrombocytopenia, danaparoid is first-line as it does not cross the placenta, according to Praxis Medical Insights 5
Fondaparinux is an alternative only where danaparoid is unavailable, though it crosses the placenta in small amounts (approximately one-tenth maternal concentration), as stated by Praxis Medical Insights 5
Vitamin K antagonists are contraindicated during first trimester and near delivery due to teratogenicity and fetal bleeding risk, as reported by Blood advances 4